Certain infectious agents, including viruses, bacteria, and parasites, can cause cancer or increase the risk that cancer will form. Some viruses can disrupt signaling that normally keeps cell growth and proliferation in check. Also, some infections weaken the immune system, making the body less able to fight off other cancer-causing infections. And some viruses, bacteria, and parasites also cause chronic inflammation, which may lead to cancer.
Most of the viruses that are linked to an increased risk of cancer can be passed from one person to another through blood and/or other body fluids. As described below, you can lower your risk of infection by getting vaccinated, not having unprotected sex, and not sharing needles.
Epstein-Barr virus (EBV)
EBV, a type of herpes virus, causes mononucleosis as well as certain types of lymphoma and cancers of the nose and throat. EBV is most commonly transmitted by contact with saliva, such as through kissing or by sharing toothbrushes or drinking glasses. It can also be spread by sexual contact, blood transfusions, and organ transplantation. EBV infection is lifelong. More than 90% of people worldwide will be infected with EBV during their lifetime, and most do not develop any symptoms. There is no vaccine to prevent EBV infection and no specific treatment for EBV infection.
Hepatitis B virus and hepatitis C virus (HBV and HCV)
Chronic infections with HBV or HCV can cause liver cancer. Both viruses can be transmitted via blood (for example, by sharing needles or through blood transfusions) and from mother to baby at birth. In addition, HBV can be transmitted via sexual contact.
Since the 1980s, infants in the United States and most other countries have been routinely vaccinated against HBV infection. Experts recommend that adults who have not been vaccinated against HBV and are at increased risk of HBV infection get vaccinated as soon as possible. Vaccination is especially important for health care workers and other professionals who come into contact with human blood.
The U.S. Centers for Disease Control and Prevention (CDC) also recommends that everyone in the United States born from 1945 through 1965, and other populations at increased risk for HCV infection, be tested for HCV. Although there is not currently a vaccine against HCV, new therapies can cure people of HCV infection. If you think you may be at risk for HBV or HCV infection, ask your doctor about being tested. These infections do not always cause symptoms, but tests can show whether you have the virus. If so, your doctor may suggest treatment. Also, your doctor can tell you how to keep from infecting other people.
Human immunodeficiency virus (HIV)
HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). HIV does not cause cancer itself, but infection with HIV weakens the immune system and makes the body less able to fight off other infections that cause cancer. People infected with HIV have increased risks of a number of cancers, especially Kaposi sarcoma, lymphomas (including both non-Hodgkin lymphoma and Hodgkin disease), and cancers of the cervix, anus, lung, liver, and throat.
HIV can be transmitted via blood and through sexual contact. Men who have unprotected sex with other men and people who share needles for injection drug use are at the highest risk of acquiring HIV infection; heterosexual individuals who have unprotected sex with multiple partners are at the next highest risk.
People can be infected with HIV for years before they begin to develop symptoms. If you think you may be at risk for HIV infection, ask your doctor about being tested. If you test positive, your doctor can prescribe highly effective antiviral treatment and can tell you how to keep from infecting other people.
Human papillomaviruses (HPVs)
Infection with high-risk types of HPV cause nearly all cervical cancers. They also cause most anal cancers and many oropharyngeal, vaginal, vulvar, and penile cancers. High-risk HPVs spread easily through direct sexual contact, including vaginal, oral, and anal sex. Several vaccines have been developed that prevent infection with the types of HPV that cause most HPV-associated cancers. In the United States, experts recommend that children be vaccinated at age 11 or 12, but children as young as age 9 and adults as old as 26 can also be vaccinated.
Cervical cancer screening can be used to detect signs of HPV infections in the cervix. Although HPV infections themselves cannot be treated, the cervical abnormalities that these infections can cause over time can be treated.
Human T-cell leukemia/lymphoma virus type 1 (HTLV-1)
HTLV-1 can cause an aggressive type of non-Hodgkin lymphoma called adult T-cell leukemia/lymphoma (ATLL). This virus spreads via blood (by sharing needles or through transfusions), through sexual contact, and from mother to child in the womb or via breastfeeding. Infection with this virus is more common in Japan, Africa, the Caribbean, and South America than in the United States. Most people with HTLV-1 infection do not have any symptoms or develop disease.
Blood is routinely screened for HTLV-1 in the United States. There is no vaccine to prevent infection with this virus and no treatment if you are infected. If you think you may be at risk for HTLV-1 infection, ask your doctor about being tested. If you test positive, your doctor can tell you how to keep from infecting other people and monitor you for HTLV-1-induced disease.
Kaposi sarcoma-associated herpesvirus (KSHV)
Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8 (HHV-8), can cause Kaposi sarcoma. KSHV can also cause primary effusion lymphoma and multicentric Castleman disease.
KSHV is most commonly spread through saliva. It can also be spread through organ or bone marrow transplantation, and there is some evidence that it can be spread by blood transfusion, although this risk is minimized by practices followed in the United States such as blood storage and removal of white cells.
KSHV infection is generally limited to certain populations, and the way KSHV is spread varies among these populations. In sub-Saharan Africa and certain regions of Central and South America, where KSHV infection is relatively common, it is believed to spread by contact with saliva among family members. In Mediterranean countries (Italy, Greece, Israel, Saudi Arabia), where KSHV infection is present at intermediate levels, it is thought to spread by contact among children and by ill-defined routes among adults. Finally, in regions where KSHV infection is uncommon, such as the United States and Northern Europe, it appears to be mostly transmitted sexually, especially among men who have sex with men.
Most people infected with KSHV do not develop cancer or show any symptoms, although those who also have HIV infection or are immunosuppressed for other reasons are more likely to develop KSHV-caused diseases. There is no vaccine to prevent KSHV infection and no therapy to treat infection. Men who have sex with men may be advised to avoid oral-anal contact (including use of saliva as a personal lubricant). And people who are infected with HIV can lower their risk of KSHV-related complications by using antiretroviral therapy.
Merkel cell polyomavirus (MCPyV)
MCPyV can cause Merkel cell carcinoma, a rare type of skin cancer. Most adults are infected with MCPyV, with transmission most likely occurring through casual direct (i.e., skin-to-skin) or indirect (i.e., touching a surface that an infected person has touched) contact in early childhood. The risk of Merkel cell carcinoma is greatly increased in elderly people and in younger adults with who are infected with HIV or are immunosuppressed for other reasons. Infection does not generally cause symptoms, and there are no treatments for MCPyV.
Helicobacter pylori (H. pylori)
H. pylori is a type of bacterium that can cause noncardia gastric cancer (a type of stomach cancer) and a type of lymphoma in the stomach lining, gastric MALT lymphoma. It can also cause stomach ulcers. The bacterium is thought to spread through consumption of contaminated food or water and direct mouth-to-mouth contact. The CDC estimates that approximately two-thirds of the world's population harbors H. pylori, with infection rates much higher in developing countries than in developed nations. In most populations, the bacterium is first acquired during childhood.
If you have stomach problems, see a doctor. Infection with H. pylori can be detected and treated with antibiotics.
This parasitic flatworm (fluke), which is found in Southeast Asia, can cause cholangiocarcinoma (cancer of the bile ducts in the liver). People become infected when they eat raw or undercooked freshwater fish that contain the larvae. Antiparasitic drugs are used to treat the infection.
This parasitic flatworm (fluke), which lives in certain types of freshwater snails found in Africa and the Middle East, can cause bladder cancer. People become infected when infectious free-swimming flatworm larvae burrow into skin that has come into contact with contaminated fresh water. Antiparasitic drugs are used to treat the infection.
Quick GuidePancreatic Cancer Symptoms, Causes, and Treatment
1. Mardis ER. ChIP-seq: welcome to the new frontier. Nat Meth. 2007;4:613–614.[PubMed]
2. Park PJ. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet. 2009;10:669–680.[PMC free article][PubMed]
3. Barski A, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129:823–837.[PubMed]
4. Johnson DS, Mortazavi A, Myers RM, Wold B. Genome-wide mapping of in vivo protein-DNA interactions. Science. 2007;316:1497–1502.[PubMed]
5. Mikkelsen TS, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. 2007;448:553–560.[PMC free article][PubMed]
6. Robertson G, et al. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat. Methods. 2007;4:651–657.[PubMed]
7. Dohm JC, Lottaz C, Borodina T, Himmelbauer H. Substantial biases in ultra-short read data sets from high-throughput DNA sequencing. Nucleic Acids Research. 2008;36:e105.[PMC free article][PubMed]
8. Rozowsky J, et al. PeakSeq enables systematic scoring of ChIP-seq experiments relative to controls. Nat Biotech. 2009;27:66–75.[PMC free article][PubMed]
9. Vega VB, Cheung E, Palanisamy N, Sung W-K. Inherent Signals in Sequencing-Based Chromatin-ImmunoPrecipitation Control Libraries. PLoS ONE. 2009;4:e5241.[PMC free article][PubMed]
10. Liu ET, Pott S, Huss M. Q&A: ChIP-seq technologies and the study of gene regulation. BMC Biol. 2010;8:56.[PMC free article][PubMed]
11. Teytelman L, et al. Impact of chromatin structures on DNA processing for genomic analyses. PLoS ONE. 2009;4:e6700.[PMC free article][PubMed]
12. Nix DA, Courdy SJ, Boucher KM. Empirical methods for controlling false positives and estimating confidence in ChIP-Seq peaks. BMC Bioinformatics. 2008;9:523.[PMC free article][PubMed]
13. Zhang Y, et al. Model-based Analysis of ChIP-Seq (MACS) Genome Biol. 2008;9:R137–R137.[PMC free article][PubMed]
14. Tavares L, et al. RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3K27me3. Cell. 2012;148:664–678.[PMC free article][PubMed]
15. Ulitsky I, Shkumatava A, Jan CH, Sive H, Bartel DP. Conserved Function of lincRNAs in Vertebrate Embryonic Development despite Rapid Sequence Evolution. Cell. 2011;147:1537–1550.[PMC free article][PubMed]
16. He HH, et al. Nucleosome dynamics define transcriptional enhancers. Nature Genetics. 2010;42:343–347.[PMC free article][PubMed]
17. Zheng W, Zhao H, Mancera E, Steinmetz LM, Snyder M. Genetic analysis of variation in transcription factor binding in yeast. Nature. 2010;464:1187–1191.[PMC free article][PubMed]
18. Noordermeer D, et al. The Dynamic Architecture of Hox Gene Clusters. Science. 2011;334:222–225.[PubMed]
19. Welboren W-J, et al. ChIP-Seq of ER|[alpha]| and RNA polymerase II defines genes differentially responding to ligands. The EMBO Journal. 2009;28:1418–1428.[PMC free article][PubMed]
20. Birney E, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799–816.[PMC free article][PubMed]
21. Liu T, et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biology. 2011;12:R83.[PMC free article][PubMed]
22. Jothi R, Cuddapah S, Barski A, Cui K, Zhao K. Genome-wide identification of in vivo protein-DNA binding sites from ChIP-Seq data. Nucleic Acids Res. 2008;36:5221–5231.[PMC free article][PubMed]
23. Ji H, et al. An integrated software system for analyzing ChIP-chip and ChIP-seq data. Nat Biotech. 2008;26:1293–1300.[PMC free article][PubMed]
24. Zang C, et al. A clustering approach for identification of enriched domains from histone modification ChIP-Seq data. Bioinformatics. 2009;25:1952–1958.[PMC free article][PubMed]
25. Fejes AP, et al. FindPeaks 3.1: a tool for identifying areas of enrichment from massively parallel short-read sequencing technology. Bioinformatics. 2008;24:1729–1730.[PMC free article][PubMed]
26. Valouev A, et al. Genome-Wide Analysis of Transcription Factor Binding Sites Based on ChIP-Seq Data. Nat Methods. 2008;5:829–834.[PMC free article][PubMed]
27. Laajala TD, et al. A practical comparison of methods for detecting transcription factor binding sites in ChIP-seq experiments. BMC Genomics. 2009;10:618.[PMC free article][PubMed]
28. Wilbanks EG, Facciotti MT. Evaluation of algorithm performance in ChIP-seq peak detection. PLoS ONE. 2010;5:e11471.[PMC free article][PubMed]
29. Pepke S, Wold B, Mortazavi A. Computation for ChIP-seq and RNA-seq studies. Nat. Methods. 2009;6:S22–S32.[PMC free article][PubMed]
30. Barski A, Zhao K. Genomic location analysis by ChIP-Seq. J. Cell. Biochem. 2009;107:11–18.[PMC free article][PubMed]
31. Malone BM, Tan F, Bridges SM, Peng Z. Comparison of four ChIP-Seq analytical algorithms using rice endosperm H3K27 trimethylation profiling data. PLoS ONE. 2011;6:e25260.[PMC free article][PubMed]
32. Chen Y, et al. Systematic evaluation of factors influencing ChIP-seq fidelity. Nature methods. 2012[PMC free article][PubMed]
33. Stitzel ML, et al. Global epigenomic analysis of primary human pancreatic islets provides insights into type 2 diabetes susceptibility loci. Cell Metab. 2010;12:443–455.[PMC free article][PubMed]
34. Sati S, et al. High Resolution Methylome Map of Rat Indicates Role of Intragenic DNA Methylation in Identification of Coding Region. PLoS One. 2012;7[PMC free article][PubMed]
35. Li N, et al. Whole genome DNA methylation analysis based on high throughput sequencing technology. Methods. 2010;52:203–212.[PubMed]
36. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.[PMC free article][PubMed]
37. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754–1760.[PMC free article][PubMed]
38. Li H, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078–2079.[PMC free article][PubMed]
39. Salmon-Divon M, Dvinge H, Tammoja K, Bertone P. PeakAnalyzer: Genome-wide annotation of chromatin binding and modification loci. BMC Bioinformatics. 11:415.[PMC free article][PubMed]
40. Robinson JT, et al. Integrative genomics viewer. Nat Biotech. 2011;29:24–26.[PMC free article][PubMed]
41. Kent WJ, et al. The human genome browser at UCSC. Genome Res. 2002;12:996–1006.[PMC free article][PubMed]
42. Nicol JW, Helt GA, Blanchard SG, Jr, Raja A, Loraine AE. The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets. Bioinformatics. 2009;25:2730–2731.[PMC free article][PubMed]